简介：Thisreviewaimsatevaluatingtheexistingevidenceregardingpostreperfusionsyndrome,providingadescriptionofthepathophysiologicmechanismsinvolvedandpossiblemanagementandpreventivestrategies.APubMedsearchwasconductedusingtheMeSHdatabase,＂Reperfusion＂AND＂livertransplantation＂werethecombinedMeSHheadings;EMBASEandtheCochranelibrarywerealsosearchedusingthesameterms.52relevantstudiesandoneongoingtrialwerefound.Theconceptofpostreperfusionsyndromehasevolvedthroughyearstoamultisystemicdisorder.Theimplicationsofthemainorgan,recipientandprocedurerelatedfactorsinthegenesisofthiscomplexsyndromearediscussedinthetextasthenovelpharmacologicandtechnicalapproachestoreduceitsincidence.Howevertheavailableevidenceaboutriskfactors,physiopathologyandpreventivemeasuresisstillconfusing,thepresenceoftwomaindefinitionsandthenumerosityofpossibleconfoundingfactorsgreatlycomplicatestheinterpretationofthestudies.

简介：AIMToverifythevalidityoftheendoscopyguidelinesforpatientstakingwarfarinordirectoralanticoagulants(DOAC).METHODSWecollecteddatafrom218patientsreceivingoralanticoagulants(73DOACusers,145warfarinusers)and218patientsnotreceivinganyantithrombotics(age-andsexmatchedcontrols)whounderwentpolypectomy.(1)Weevaluatedpost-polypectomybleeding(PPB)riskinpatientsweassessedtherisksofPPBandthromboembolismbetweenthreeACmanagementmethods:DiscontinuingACwithheparinbridge(HPB)(endoscopyguidelinerecommendation),continuingAC,anddiscontinuingACwithoutHPB.RESULTSPPBratewassignificantlyhigherinwarfarinusersandDOACuserscomparedwithcontrols(13.7%and13.7%vs0.9%,P<0.001),butwasnotsignificantlydifferentbetweenrivaroxaban(13.2%),dabigatran(11.1%),andapixaban(13.3%)users.Twothromboemboliceventsoccurredinwarfarinusers,butnoneinDOACusers.Comparedwiththecontinuinganticoagulantgroup,thediscontinuinganticoagulantwithHPBgroup(guidelinerecommendation)hadahigherPPBrate(10.8%vs19.6%,P=0.087).ThesefindingsweresignificantlyevidentinwarfarinbutnotDOACusers.OnethromboticeventoccurredinthediscontinuinganticoagulantwithHPBgroupandthediscontinuinganticoagulantwithoutHPBgroup;noneoccurredinthecontinuinganticoagulantgroup.CONCLUSIONPPBriskwassimilarbetweenpatientstakingwarfarinandDOAC.Thromboembolismwasobservedinwarfarinusersonly.TheguidelinerecommendationsforHPBshouldbere-considered.